Cordlife (SGX:P8A) received letters of demand from two groups of persons for cord blood units stored with the company, according to a filing with the Singapore Exchange on Tuesday.
The persons claim that the cord blood units stored by the company are either unlikely to be suitable for stem cell transplant purposes or fall within the low risk or unaffected category, and have requested compensation.
The company is now seeking legal advice and will respond to the solicitors of the two persons in due course.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.